InsiderSignal.AI

InsiderSignal.ai

MGNX - Macrogenics Inc

Insider Purchase by Heiden William K (Dir)

1 Year
After Trade
Before Trade

Loading data...

Trade Summary

6 months ago, Heiden William K, serving as Dir at Macrogenics Inc (MGNX), purchased 100,000 shares at $1.51 per share, for a total transaction value of $150,515.00. Following this transaction, Heiden William K now holds 111,000 shares of MGNX.

This purchase represents a 909.00% increase in Heiden William K's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, August 19, 2025 and publicly disclosed via SEC Form 4 filing on Thursday, August 21, 2025, 2 days after the trade was made.

Macrogenics Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Heiden William K

Dir

William K. Heiden, age 65, is the independent Chair of the Board of Directors at MacroGenics, Inc. (MGNX) since May 2022, where he also serves on the Audit Committee as the designated financial expert and chairs the Human Capital Management Committee.[[1]](https://fintool.com/app/research/companies/MGNX/people/william-heiden)[[2]](https://www.marketscreener.com/insider/WILLIAM-HEIDEN-A04MLM/) In August 2025, he purchased 100,000 shares of MGNX common stock over two days at prices around $1.49–$1.52 per share, increasing his direct ownership to 111,000 shares valued at approximately $190,920.[[3]](https://www.tradingview.com/news/tradingview:323daad847373:0-macrogenics-director-william-k-heiden-acquires-100-000-shares/)[[4]](https://www.gurufocus.com/insider/30822/william-k-heiden)[[5]](https://www.stocktitan.net/sec-filings/MGNX/form-4-macro-genics-inc-insider-trading-activity-253462e42759.html) Heiden brings over 35 years of biopharma leadership experience, including roles as President and CEO at AMAG Pharmaceuticals (2012–2020), Genzyme Transgenics Company (2010–2012), and Elixir Pharmaceuticals (2004–2008), as well as President and COO at Praecis Pharmaceuticals (2002–2004) and various positions at Schering-Plough (1987–2002).[[1]](https://fintool.com/app/research/companies/MGNX/people/william-heiden)[[2]](https://www.marketscreener.com/insider/WILLIAM-HEIDEN-A04MLM/) He currently serves as an independent director at Atara Biotherapeutics (since 2015) and holds other board positions including at Third Pole, Inc., Corea Therapeutics, and Revo Biologics.[[2]](https://www.marketscreener.com/insider/WILLIAM-HEIDEN-A04MLM/) Heiden holds a BA in Finance from the University of Florida, an MBA from Cornell University, and a Master’s in International Management from the University of Louvain, Belgium.[[1]](https://fintool.com/app/research/companies/MGNX/people/william-heiden)[[2]](https://www.marketscreener.com/insider/WILLIAM-HEIDEN-A04MLM/)

View full insider profile →

Trade Price

$1.51

Quantity

100,000

Total Value

$150,515.00

Shares Owned

111,000

Trade Date

Tuesday, August 19, 2025

187 days ago

SEC Filing Date

Thursday, August 21, 2025

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Macrogenics Inc

Company Overview

No company information available
View news mentioning MGNX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/144729

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime